CSTL vs NEO
CSTL: Castle Biosciences is a molecular diagnostics company offering gene expression profile tests to improve management of dermatologic and gastrointestinal cancers. NEO: NeoGenomics is a clinical laboratory leader providing specialized cancer-focused genetic and molecular testing services for diagnostics and pharmaceutical research.
Side-by-side fundamentals
| Metric | CSTL | NEO | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $28.00 | $13.14 | |
| Market cap as of 2026-08-03 | $855M | $1.7B | |
| PEG as of 2026-08-03 | -0.50 | 1.27 | CSTL lower |
| Net margin as of 2026-08-03 | -3.8% | -13.3% | CSTL higher |
| Gross margin as of 2026-08-03 | +77.9% | +43.1% | CSTL higher |
| Operating margin as of 2026-08-03 | -9.8% | -14.3% | CSTL higher |
| ROE as of 2026-08-03 | -2.8% | -11.8% | CSTL higher |
| ROA as of 2026-08-03 | -2.3% | -7.2% | CSTL higher |
| Debt / equity as of 2026-08-03 | 0.03 | 0.41 | CSTL lower |
| Revenue growth (YoY) as of 2026-08-03 | -2.1% | +10.9% | NEO higher |
| Revenue CAGR (3y) SEC XBRL | +35.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-08-03 | 0.88 | 1.78 | |
| 1-year return as of 2026-07-31 close | +84.8% | +108.9% | NEO higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.